Alzheimer’s drug, the monoclonal antibody lecanemab, slowed decline in a phase 3 clinical trial, the company said.
Related Articles
-
FDA issues a new alert about lead contamination in ground cinnamon
The Food and Drug Administration said in a new alert Thursday that it has identified an additional cinnamon product...
-
WHO warns of ‘real’ risk that monkeypox will become established outside Africa
World Health Organization Director-General Tedros Adhanom Ghebreyesus cautioned Wednesday that the window to contain the global monkeypox outbreak may be narrowing....
-
The WHO overturned dogma on how airborne diseases spread. Will the CDC act on it?
The World Health Organization has issued a report that transforms how the world understands respiratory infections like Covid, influenza...
-
CDC recommends RSV vaccine given during pregnancy to protect babies
Pregnant people should get an RSV vaccine at 32 to 36 weeks’ gestation in order to protect their newborns...
-
About 100 U.S. athletes in Tokyo unvaccinated as Olympics begin
TOKYO — Five out of 6 U.S. athletes competing in the Tokyo Olympics have been vaccinated against Covid-19, the...
-
How one reporter’s lens of Covid changed when it landed on his parents’ doorstep
Claudio Lavanga, NBC News’ Rome correspondent, has reported on a wide variety of stories. Most recently, he has helped...
-
A new version of omicron is gaining a foothold in the U.S., CDC finds
Another omicron subvariant is gaining traction in the United States, the Centers for Disease Control and Prevention reported Tuesday....
-
CDC says skin-disfiguring parasite may be endemic in Texas, present in other states
A parasite capable of causing a disfiguring skin disease may be endemic in Texas and present in other southern states, according...
Recent Comments